News Column

Investigators from Nagasaki University Report New Data on DNA Vaccines

June 17, 2014

By a News Reporter-Staff News Editor at World Disease Weekly -- Current study results on Biotechnology have been published. According to news reporting originating in Nagasaki, Japan, by NewsRx journalists, research stated, "We have previously reported the new formulation of polyethylimine (PEI) with gamma polyglutamic acid (gamma-PGA) nanoparticle (NP) to have provided Plasmodium yoelii merozoite surface protein-1 (PyMSP-1) plasmid DNA vaccine with enhanced protective cellular and humoral immunity in the lethal mouse malaria model. PyGPI8p-transamidase-related protein (PyTAM) was selected as a possible candidate vaccine antigen by using DNA vaccination screening from 29 GPI anchor and signal sequence motif positive genes picked up using web-based bioinformatics tools; though the observed protection was not complete."

The news reporters obtained a quote from the research from Nagasaki University, "Here, we observed augmented protective effect of PyTAM DNA vaccine by using PEI and gamma-PGA complex as delivery system. NP-coated PyTAM plasmid DNA immunized mice showed a significant survival rate from lethal P. yoelii challenge infection compared with naked PyTAM plasmid or with NP-coated empty plasmid DNA group. Antigen-specific IgG1 and IgG2b subclass antibody levels, proportion of CD4 and CD8T cells producing IFN-gamma in the splenocytes and IL-4, IFN-gamma, IL-12 and TNF-alpha levels in the sera and in the supernatants from ex vivo splenocytes culture were all enhanced by the NP-coated PyTAM DNA vaccine."

According to the news reporters, the research concluded: "These data indicates that NP augments PyTAM protective immune response, and this enhancement was associated with increased DC activation and concomitant IL-12 production."

For more information on this research see: Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model. Vaccine, 2014;32(17):1998-2006. Vaccine can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier -; Vaccine -

Our news correspondents report that additional information may be obtained by contacting M.S. Cherif, Nagasaki University, Inst Trop Med, Prod Dev Department, Nagasaki 852, Japan. Additional authors for this research include M.N. Shuaibu, Y. Kodama, T. Kurosaki, G.K. Helegbe, M. Kikuchi, A. Ichinose, T. Yanagi, H. Sasaki, K. Yui, N.H. Tien, J. Karbwang and K. Hirayama (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Japan, Nagasaki, Genetics, DNA Research, DNA Vaccines, Malaria Vaccines, Protozoan Vaccines, Synthetic Vaccines, Biological Products, Protozoan Infections

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: World Disease Weekly

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters